Pharmaceutical Technology2d
Flu vaccine strategy on the line as new US leaders anticipated to take charge
As countries in the Northern hemisphere deal with the flu season, experts say regulation surrounding flu vaccines could be due for a shake up with new healthcare leaders set to take charge in the US.
Pharmaceutical Technology1d
Risk adjusted net present value: What is the current valuation of Pfizer’s Inclacumab?
Inclacumab is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease With Vaso-Occlusive Crisis.
Pharmaceutical Technology1d
Risk adjusted net present value: What is the current valuation of Tyra Biosciences’s TYRA-300?
TYRA-300 is a small molecule commercialized by Tyra Biosciences, with a leading Phase II program in Solid Tumor.
Pharmaceutical Technology1d
ASH 2024 discussions shine spotlight on advances in haemophilia treatments
When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a handful said yes.
Pharmaceutical Technology2d
AIM ImmunoTech gains Netherlands patent for post-Covid fatigue therapy
AIM ImmunoTech has secured a patent from the Netherlands Patent Office for Ampligen, targeting the treatment of post-Covid fatigue.
Pharmaceutical Technology2d
China NMPA approves Santhera’s DMD treatment therapy
China’s NMPA has granted approval to Santhera Pharmaceuticals’ AGAMREE, used in treating DMD in individuals aged four years and above.
Pharmaceutical Technology2d
Risk adjusted net present value: What is the current valuation of Teva Pharmaceutical Industries’s Aflibercept Biosimilar?
Aflibercept Biosimilar is a fusion protein commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Wet (Neovascular / Exudative) Macular Degeneration.
Pharmaceutical Technology2d
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s HS-001?
HS-001 is a cell therapy commercialized by Novo Nordisk, with a leading Phase II program in Systolic Heart Failure.
Pharmaceutical Technology1d
Risk adjusted net present value: What is the current valuation of Solid Biosciences’s SGT-003?
SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy.
Pharmaceutical Technology1d
Risk adjusted net present value: What is the current valuation of Black Diamond Therapeutics’s BDTX-1535?
BDTX-1535 is a small molecule commercialized by Black Diamond Therapeutics, with a leading Phase II program in Non-Small Cell Lung Cancer.
Pharmaceutical Technology2d
Risk adjusted net present value: What is the current valuation of Tempest Therapeutics’s TPST-1120?
TPST-1120 is a small molecule commercialized by Tempest Therapeutics, with a leading Phase II program in Metastatic Hepatocellular Carcinoma (HCC).